SAMSRITA.BO · BSE
SAMSRITA LABS LIMITED
₹11.61
+0.09% (+₹0.01)
Prev. close
₹11.6
Volume
429
As of
BSE · may be slightly delayed · 14:05 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SAMSRITA LABS LIMITED
Samsrita Labs Limited operates as a biopharmaceutical company in India. It offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and fluorescence in-situ hybridization analysis. The company is also involved in the stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffold development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology for the body organs of the liver, pancreas, neural, cardiac, vascular, renal, and orthopedic systems. In addition, it engages in new drug discovery, targeting therapeutic areas, such as Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular disease, cystinosis, and Huntington's disease. Further, the company provides molecular prognosis and diagnostic services in the areas of cytogenetics, pharmacogenomics, pathology, radiology, hematology, biochemistry, microbiology, and others; and develops liver support devices, bioengineered implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, and extracorporeal devices, as well as contract research and manufacturing services. Additionally, it offers molecular diagnostics services to patients, private consultants, academic and hospital services, hospitals, and other healthcare institutions. The company was formerly known as Dr. Habeebullah Life Sciences Limited and changed its name to Samsrita Labs Limited in October 2022. Samsrita Labs Limited was incorporated in 1996 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Krishnam Raju Kalidindi
Headquarters
Hyderabad
Employees
5
Website
drhlsl.comExchange
View on BSE ↗Key stats
Market cap
₹26.39 Cr
EPS (TTM)
₹-3.88
Beta (1Y · daily vs NIFTY 50)
-0.14
Beta (5Y · monthly vs NIFTY 50)
0.86
Shares float
50.12 L
EPS · quarter ended Jun 2026
₹-0.08
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.6% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1.30 L | ₹2.30 L | ₹2.16 L | ₹0 | ₹0 | ₹1.81 L | |
| EBITDA | — | — | ₹-24.94 L | ₹-24.60 L | ₹-25.67 L | ₹-77.23 L |
| ₹-77.00 L | ₹1.50 Cr | ₹-70.57 L | ₹-26.22 L | ₹-28.48 L | ₹-8.16 Cr | |
| Diluted EPS | — | — | ₹-0.48 | ₹-0.18 | ₹-0.19 | ₹-3.99 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹15.56 Cr | ₹15.55 Cr | ₹15.57 Cr | ₹14.38 Cr | |
| — | — | ₹2.08 Cr | ₹2.20 Cr | ₹2.43 Cr | ₹1.66 Cr | |
| Stockholders' equity | — | — | ₹12.52 Cr | ₹12.26 Cr | ₹11.97 Cr | ₹11.75 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31, 2024-03-31, 2025-03-31, 2026-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2023-03-31, 2024-03-31, 2025-03-31, 2026-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹66.12 L | ₹-12.86 L | ₹-22.55 L | ₹-4.26 Cr | |
| Investing cash flow | — | — | ₹0 | ₹0 | ₹0 | ₹3.26 Cr |
| Financing cash flow | — | — | ₹66.52 L | ₹12.77 L | ₹22.36 L | ₹2.63 Cr |
| End cash position | — | — | ₹52,000 | ₹42,700 | ₹24,210 | ₹1.63 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| SAMSRITA LABS LIMITED | ₹26.84 Cr | ₹11.8 | — | 2.28 | -69.4% | 0.14 | — | -36.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 16
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.